The US Food and Drug Administration has issued a tentative approval letter related to the New Drug Application for Noven Pharmaceuticals' Stavzor (valproic acid delayed-release capsules) in 125mg, 250mg and 500mg strengths. This relates to the use of the drug in the treatment of manic episodes associated with bipolar disorder, monotherapy and adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.
The FDA states in the letter that it has completed its review of the amended Stavzor NDA and that it is tentatively approved, which generally means that the agency has concluded that a drug product has met all required quality, safety and efficacy standards but, because of existing patents and/or exclusivity rights, it cannot yet be marketed in the USA. The NDA for Stavzor, which was submitted by Banner Pharmacaps (the NDA holder and developer of the product) under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, references Abbott Laboratories' Depakote (valproic acid) product. Based on receipt of the letter and Noven's understanding of Depakote exclusivity, the firm says it continues to expect final FDA approval of its product by the end of July 2008.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze